Iktos
Developing AI solutions for drug discovery
Iktos develops artificial intelligence (AI) solutions for the drug discovery and new drug design. Iktos’ proprietary and innovative technology is based on generative deep learning models, which allow, from existing data, to design optimized molecules in silico to meet all the success criteria of a small molecule discovery. Iktos is the only company to offer generative modeling with built-in synthetic accessibility for successful drug discovery and has already validated its technology through more than 50 collaborations with pharmaceutical and biotech companies such as Chiesi Group, Galapagos, Janssen, Merck KGaA, Darmstadt, Germany, Teijin, Ono Pharmaceuticals, Pfizer, Servier, UCB, etc.
